Vitamin K2 Market Size
The global market size of vitamin K2 is expected to reach US$290 million in 2026, with a compound growth rate of 24.5%. Among them, Menaquinone 7 accounts for approximately 46-49% of the Vitamin K2 market size. Nearly 60% of the ingredients in Menaquinone 7 are fermented, and the remainder are synthetic.
In 2023, the Menaquinone 7 market size will be approximately US$75 million. Among them, the fermentation MK-7 market size is US$50 million. Based on an estimated average price of US$250/kg, the tonnage of fermented MK-7 is approximately 180 tons, and synthetic MK-7 is approximately 120 tons. (MK-7 is calculated as 2000ppm)
Vitamin K2 Menaquinone-7 Clinical Trials Overview
Vitamin K is essential for bone health.
Clinical Trials One
Most countries’ recommended daily intake (RDI) of vitamin K currently is based on normal clotting requirements. Vitamin K1 and Vitamin K2 MK-4 have been shown to reduce RDI levels of osteocalcin (OC) gamma-carboxylation. Among various vitamin K homologs, only Vitamin K2 Menaquinone-7 can promote γ-carboxylation of extrahepatic VKDP, OC, and matrix Gla proteins at nutritional doses around the RDI.
MK-7 has higher bioavailability and a longer half-life than other vitamin K congeners. Hence, higher efficacy. It can increase bone mineral density and promote bone mass and strength. In addition, collagen production and bone quality may also be affected by MK-7 or MK-4, which is converted from MK-7.
Clinical Trials Two
Regarding the issue of “What is the lowest daily dose of Menaquinone-7 that is effective in improving osteocalcin gamma-carboxylation?” a research team conducted two experiments. The first was a double-blind, randomized, controlled dose trial. The study selected 60 postmenopausal women aged 50-69 years and assigned them to four dosage groups, consuming 0, 50, 100, or 200 μg of Menaquinone-7 per day. Continue for four weeks and follow a diet based on the 2010 recommended daily intake.
In addition, an experiment was conducted based on the above research results. 120 subjects aged 20 to 69 years were assigned to placebo or menaquinone-7, receiving 0 or 100 μg of menaquinone-7 per day, respectively. It lasts 12 weeks.
In both studies, circulating carboxylated osteocalcin and insufficient carboxylated osteocalcin were measured. In the 0 μg menaquinone-7 group, the ratio of carboxylated osteocalcin and undercarboxylated osteocalcin decreased obviously from baseline. In it, subjects consumed the recommended daily amount of vitamin K and vitamin K1 and menaquinone-4. Menaquinone-7 dose-dependently increases the carboxylated osteocalcin/carboxylated osteocalcin ratio. Compared with the 0 μg group, significant effects were observed in the 100 and 200 μg groups. The carboxylated osteocalcin concentration was significantly lower, and the carboxylated osteocalcin/carboxylated osteocalcin ratio was significantly higher in the 100 μg menaquinone-7 group compared with the placebo group.
Clinical Trials Three
In healthy children, the relationship between increased vitamin K2 daily intake and enhanced osteocalcin carboxylation is also worth attention. This study aimed to examine the effects of 45 mcg menaquinone-7 on circulating levels of carboxylated osteocalcin (ucOC) and carboxylated osteocalcin (cOC) in healthy prepubertal children. MK-7 supplementation was hypothesized to decrease the ucOC:cOC ratio (UCR), indicating improved vitamin K status. In a double-blind, randomized, placebo-controlled trial, researchers examine the effect of 8 weeks of MK-7 supplementation on osteocalcin carboxylation in healthy children (n 55). Serum levels of ucOC, cOC, and MK-7, as well as bone markers and coagulation parameters, were measured at baseline and after 8 weeks. UCR is used as an indicator of vitamin K status. In the MK-7-supplemented group (n 28), circulating concentrations of inactive ucOC decreased, and UCR improved, while MK-7 concentrations increased. In the placebo group, ucOC, cOC, UCR, and MK-7 did not change significantly over time.
In both groups, bone markers and coagulation parameters remained constant over time. These findings suggest that in healthy prepubertal children, moderate MK-7 supplementation increases circulating concentrations of MK-7 and osteocalcin carboxylation.
Main Specifications Of Vitamin K2 Menaquinone 7
- Vitamin K2 Menaquinone 7 Oil 1,500ppm/2,000ppm
This specification is a light yellow liquid. Made with soybean oil as an auxiliary ingredient.
- Vitamin K2 Powder Menaquinone 7 2,000ppm
The appearance of Vitamin K2 powder is mainly white to light yellow. Made with maltodextrin as an excipient. Another powder option is Vitamin K2 Embedded Powder. There are relatively many excipients in this specification, including edible corn starch, white sugar, vitamin E, sodium octenyl starch succinate, etc.
- Vitamin K2 Pure Menaquinone 7 96% Purity Min
Conclusion
Vitamin K, specifically Vitamin K2 Menaquinone 7, has proven benefits for bone health. Furthermore, Menaquinone 7 is more bioavailable than MK-4.
Therefore, Nutri Avenue recommends Vitamin K2 Menaquinone 7 from all major bone brands. Moreover, our Menaquinone 7 is produced through the fermentation process. High-purity products and no solvent residues are guaranteed. Able to achieve fast and stable supply. This ingredient is also tested by a third party and certified by Kosher, Halal, etc. All these things can ensure our product quality. If you are interested in it, welcome to contact our sales team to know more. We can provide its COA, price, and more information.
Sources:
